Advanced Search
Welcome to the Systematic
Review Data Repository
Welcome to the Systematic Review Data Repository
The Systematic Review Data Repository (SRDR) is a powerful and easy-to-use tool for the extraction and management of data for systematic review or meta-analysis. It is also an open and searchable archive of systematic reviews and their data.

To contribute data or comment on deposited projects, simply Register for an account.

Registered users, log in below:
Forgot Password?

Recently Completed and Deposited Reports Data

Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents

Public Report Complete
Statistics: 97 Studies, 2 Key Questions, 1 Extraction Form,
Date Created: Apr 09, 2015 07:54PM
Description: None Provided

Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer

Public Report Complete
Statistics: 17 Studies, 1 Key Question, 1 Extraction Form,
Date Created: Jun 04, 2014 06:13PM
Description: The purpose of this technical brief is to understand current utilization of metastatic breast imaging modalities for treatment evaluation in the United States, both in order to summarize the current state of the science and to inform future research on this topic.

Imaging for the Pretreatment Staging of Small Cell Lung Cancer

Public Report Complete
Statistics: 7 Studies, 3 Key Questions, 1 Extraction Form,
Date Created: Jun 27, 2014 11:38PM
Description: Systematic Review for AHRQ EPC Program

Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer

Public Report Complete
Statistics: 199 Studies, 8 Key Questions, 1 Extraction Form,
Date Created: May 18, 2015 07:06PM
Description: Objectives. Non-muscle-invasive bladder cancer (NMIBC) frequently recurs and can progress to muscle-invasive disease. This report reviews the current evidence on emerging approaches to diagnosing and treating bladder cancer. Data Sources. Electronic databases (Ovid MEDLINE, January 1990 – October 2014; Cochrane Central Register of Controlled Trials, through September 2014; Cochrane Database of Systematic Reviews, through September 2014; Health Technology Assessment, through 3rd Quarter, 2014; National Health Sciences Economic Evaluation Database, through 3rd Quarter, 2014; and Database of Abstracts of Reviews of Effects, through 3rd Quarter, 2014), references lists, and clinical trials registries. Review Methods. Using predefined criteria, we selected studies on diagnostic accuracy of urinary biomarkers versus cystoscopy, and trials of fluorescent cystoscopy, intravesical therapy, and radiation therapy for NMIBC that evaluated bladder cancer recurrence, progression, mortality, or harms. The quality of included studies was assessed, data were extracted, and results were summarized qualitatively and using meta-analysis. Results. Urinary biomarkers were associated with sensitivity for bladder cancer that ranged from 0.57 to 0.82 and specificity from 0.74 to 0.88, for positive likelihood ratios from 2.52 to 5.53 and negative likelihood ratios from 0.21 to 0.48 (strength of evidence [SOE]: moderate for quantitative nuclear matrix protein 22 [NMP22], qualitative bladder tumor antigen [BTA], fluorescent in situ hybridization [FISH], and ImmunoCyt; low for other biomarkers). Sensitivity increased for higher stage and grade tumors. Studies that directly compared the accuracy of quantitative NMP22 and qualitative BTA found no differences in diagnostic accuracy (SOE: moderate). Most trials found fluorescent cystoscopy associated with decreased risk of subsequent bladder recurrence versus white light cystoscopy, but results were inconsistent, and there was no difference in risk of progression or mortality (SOE: low). Intravesical therapy was more effective than no intravesical therapy for reducing risk of bladder cancer recurrence (for bacillus Calmette-Guérin [BCG], RR 0.56, 95% CI 0.43 to 0.71, SOE: moderate; for mitomycin C [MMC], doxorubicin, and epirubicin, RR 0.66 to 0.72, SOE: moderate). BCG was also associated with decreased risk of bladder cancer progression, but no intravesical agent was associated with decreased risk of all-cause or bladder-cancer specific mortality. Intravesical therapy appeared to be effective across subgroups defined by tumor stage, grade, multiplicity, recurrence status, and size (SOE: low). Evidence was too limited to draw strong conclusions regarding effects of dose or duration of therapy on effectiveness. Compared with no intravesical therapy, BCG was associated with a higher rate of local and systemic adverse events (granulomatous cystitis or irritative symptoms in 27% to 84% of patients, macroscopic hematuria in 21% to 72%, and fever in 27% to 44%) (SOE: low). Compared with MMC, BCG was also associated with an increased risk of local adverse events and fever (SOE: low). One randomized trial found no difference between radiation therapy and no radiation therapy in clinical outcomes in patients with T1G3 cancers. Conclusions. Urinary biomarkers miss a substantial proportion of patients with bladder cancer, and additional research is needed to clarify advantages of fluorescent cystoscopy over white light cystoscopy. Intravesical therapy reduces risk of bladder cancer recurrence versus no intravesical therapy. BCG is the only intravesical therapy shown to be associated with decreased risk of bladder cancer progression, but is associated with a high rate of adverse events. More research is needed to define optimal doses and regimens of intravesical therapy.

Dietary Fiber Database, Version 1

Public Report Complete
Statistics: 868 Studies, 1 Key Question, 1 Extraction Form,
Date Created: Apr 27, 2015 09:35PM
Description: The objectives of this database are to: 1. Systematically compile and provide access to primary, English-language, peer-reviewed science linking dietary fiber intake in humans to one or more of 9 potential health benefits 2. Provide researchers with a tool to understand how different fibers are characterized in studies 3. Facilitate researchers in identifying gaps in the current research 4. Create a database to serve as a starting foundation of primary human literature for conducting evidence-based reviews and meta-analyses 5. Efficiently assist researchers in identifying fibers of interest This database should serve as a foundation for future work. Specific inclusion and exclusion criteria, detailed in the user manual, were applied in determining database eligibility; thus, this database is not intended to serve as a sole source for identifying all possible fiber literature for the purposes of conducting a meta-analysis or systematic review. This database contains Population, Intervention, Comparator, and Outcome (PICO) data to help users formulate and narrow the focus of their research question. It is expected that secondary searches will be conducted to augment this database.

Health Information Exchange

Public Report Complete
Statistics: 136 Studies, 8 Key Questions, 1 Extraction Form,
Date Created: Apr 24, 2015 07:53PM
Description: None Provided

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See:

Popular Resources


SRDR Announcements



Maintenance Schedule